Tirzepatide is the first FDA-approved medication that activates two incretin hormone receptors simultaneously: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Unlike semaglutide-based medications such as Ozempic and Wegovy, which target only GLP-1, tirzepatide targets both pathways at once. This dual action earned it the nickname “twincretin” among researchers.
In the SURMOUNT 1 trial, participants lost an average of 20.9% of their body weight over 72 weeks, demonstrating promising results that can inspire hope and confidence in your weight-loss journey.
Green Relief Health offers supervised tirzepatide treatment programs tailored to your health profile. Our providers determine the right medication and dose based on your goals and medical history.
Book Your Weight Loss Consultation Today
What You’ll Learn
- What Are GLP-1 and GIP?
- How Tirzepatide Works in the Body: Step by Step
- What Makes Tirzepatide Different from Semaglutide?
- Clinical Trial Results: The SURMOUNT Program
- FDA-Approved Uses for Tirzepatide
- Side Effects and Safety Profile
- What to Expect When Starting Tirzepatide
- Frequently Asked Questions
What Are GLP-1 and GIP?
GLP-1 and GIP are incretin hormones. Your gut releases them naturally after you eat. Both hormones signal your pancreas to produce insulin, which lowers blood sugar. They also communicate with your brain to regulate appetite and feelings of fullness.
GLP-1 (glucagon-like peptide 1) slows the rate at which food leaves your stomach (gastric emptying), reduces appetite by acting on hunger centers in the brain, and stimulates glucose-dependent insulin secretion. This is the single pathway that medications like Ozempic and Wegovy target.
GIP (glucose-dependent insulinotropic polypeptide) enhances insulin secretion, influences fat metabolism, and appears to work synergistically with GLP-1 to amplify appetite suppression and weight loss. Research published in Molecular Metabolism demonstrated that co-activation of GIP and GLP-1 receptors produced greater weight reduction in animal models than GLP-1 activation alone.
Tirzepatide is a synthetic 39-amino acid peptide engineered from the native human GIP molecule. It binds to GIP receptors with an affinity equal to natural GIP, while its GLP-1 receptor affinity is approximately 5 times weaker than native GLP-1. This “imbalanced” agonism is a deliberate design feature and contributes to its unique clinical profile.
How Tirzepatide Works in the Body: Step by Step
You inject tirzepatide once weekly. A fatty acid chain attached to the molecule extends its half-life to approximately 5 days. This allows once weekly dosing at 5 mg, 10 mg, or 15 mg.
Tirzepatide activates GIP and GLP-1 receptors. Both receptor types exist in the pancreas, brain, gut, and adipose tissue. By activating both simultaneously, tirzepatide triggers overlapping but distinct metabolic responses.
Activation of the GLP-1 receptor in the hypothalamus reduces hunger signals. GIP receptor activation amplifies this effect. Most patients notice appetite suppression within the first 1 to 2 weeks of treatment.
Food stays in your stomach longer, extending the feeling of fullness after meals. This naturally reduces caloric intake without requiring rigid portion control.
Tirzepatide improves both first and second-phase insulin secretion. In the SURPASS clinical trials for type 2 diabetes, tirzepatide reduced HbA1c by 1.24% to 2.58%, with up to 62.4% of patients reaching normal blood sugar levels below 5.7%.
What Makes Tirzepatide Different from Semaglutide?
The most important distinction is receptor targeting. Semaglutide (the active ingredient in Ozempic and Wegovy) activates only GLP-1 receptors. Tirzepatide activates both GLP-1 and GIP receptors, producing additive metabolic benefits.
The SURMOUNT 5 trial, published in the New England Journal of Medicine in 2025, provided the first head-to-head comparison. Over 72 weeks, 751 adults with obesity (without diabetes) were randomized to receive tirzepatide or semaglutide at maximum tolerated doses.
Tirzepatide provided 47% greater relative weight loss compared to semaglutide. Patients on tirzepatide were also twice as likely to achieve 25% or greater body weight reduction.
Clinical Trial Results: The SURMOUNT Program
Tirzepatide’s weight loss efficacy was established in the SURMOUNT phase 3 clinical trials.
| Trial | Population | Dose | Avg Weight Loss | Duration |
|---|---|---|---|---|
| SURMOUNT 1 | Obesity without diabetes | 5/10/15 mg | 15-20.9% | 72 weeks |
| SURMOUNT 5 | Obesity without diabetes | Max tolerated | 20.2% (vs 13.7% semaglutide) | 72 weeks |
In SURMOUNT 1, over 50% of patients taking the 10 mg or 15 mg dose lost more than 20% of their body weight. Only 3% of the placebo group achieved the same result.
FDA-Approved Uses for Tirzepatide
Tirzepatide is currently marketed under two brand names with distinct FDA-approved indications:
- Mounjaro received FDA approval in May 2022 for improving glycemic control in adults with type 2 diabetes.
- Zepbound received FDA approval in November 2023 for chronic weight management in adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity.
Both Zepbound and Mounjaro contain the same tirzepatide doses, but their FDA-approved uses differ.
Side Effects and Safety Profile
The most common side effects are gastrointestinal, such as nausea and diarrhea, which are usually mild and temporary.
Tirzepatide also reduced blood pressure (6.8 mm Hg systolic, 4.2 mm Hg diastolic vs placebo), improved triglycerides by up to 24.9%, and increased HDL cholesterol. These cardiometabolic benefits extend beyond weight loss.
Some patients report sulfur burps or GI discomfort during the initial weeks. These symptoms typically resolve as the body adjusts. Side effects from incretin-based medications generally improve within 4 to 8 weeks.
What to Expect When Starting Tirzepatide
Treatment begins at 2.5 mg weekly for 4 weeks. Your provider increases the dose every 4 weeks based on your tolerance: 2.5 mg, then 5 mg, then 7.5 mg, then 10 mg, then 12.5 mg, up to a maximum of 15 mg. This gradual titration takes up to 20 weeks to reach the highest dose.
Most patients notice meaningful changes in appetite within the first 2 weeks. Visible weight loss typically begins in weeks 4 to 8 as the dose increases.
Start Your Tirzepatide Treatment in Baltimore
Green Relief Health provides medically supervised tirzepatide programs with ongoing support. Our providers create a personalized plan based on your BMI, health history, and weight loss goals.
Call (410) 368-04207690 Belair Road, Suite 1, Baltimore, MD 21236
Frequently Asked Questions
Yes. The SURMOUNT 5 trial showed that tirzepatide produced 20.2% weight loss compared with 13.7% with semaglutide over 72 weeks. This represents 47% greater relative weight reduction with tirzepatide.
Most patients experience appetite suppression within 1 to 2 weeks. Measurable weight loss begins within 4 to 8 weeks as the dose increases. Full results develop over 20 to 72 weeks, depending on the target dose.
Yes. Tirzepatide is FDA-approved for both indications under different brand names. Mounjaro is approved for type 2 diabetes, and Zepbound is approved for chronic weight management. Your provider determines which is appropriate based on your diagnosis.
Both contain tirzepatide at identical doses. The difference is the FDA-approved indication. Mounjaro is indicated for type 2 diabetes. Zepbound is indicated for weight management in adults with obesity or overweight with at least one weight-related comorbidity.
Ready to Get Started?
Schedule your consultation with our expert team for personalized treatment.
Call (410) 368-04207690 Belair Road, Suite 1, Baltimore, MD 21236
